GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (LTS:0HL9) » Definitions » Cyclically Adjusted PS Ratio

Affimed NV (LTS:0HL9) Cyclically Adjusted PS Ratio : 1.97 (As of Jun. 09, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Affimed NV Cyclically Adjusted PS Ratio?

As of today (2024-06-09), Affimed NV's current share price is $6.10. Affimed NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $3.09. Affimed NV's Cyclically Adjusted PS Ratio for today is 1.97.

The historical rank and industry rank for Affimed NV's Cyclically Adjusted PS Ratio or its related term are showing as below:

LTS:0HL9' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.91   Med: 1.9   Max: 6.52
Current: 1.94

During the past years, Affimed NV's highest Cyclically Adjusted PS Ratio was 6.52. The lowest was 0.91. And the median was 1.90.

LTS:0HL9's Cyclically Adjusted PS Ratio is ranked better than
74.01% of 504 companies
in the Biotechnology industry
Industry Median: 5.47 vs LTS:0HL9: 1.94

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Affimed NV's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.030. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $3.09 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Affimed NV Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Affimed NV's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Cyclically Adjusted PS Ratio Chart

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 3.71 1.97

Affimed NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.71 2.16 1.72 1.36 1.97

Competitive Comparison of Affimed NV's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Affimed NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affimed NV's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affimed NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Affimed NV's Cyclically Adjusted PS Ratio falls into.



Affimed NV Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Affimed NV's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=6.10/3.09
=1.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Affimed NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Affimed NV's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.03/123.7729*123.7729
=0.030

Current CPI (Dec. 2023) = 123.7729.

Affimed NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.417 99.543 0.519
201406 0.420 99.543 0.522
201409 1.017 99.823 1.261
201412 0.042 99.543 0.052
201503 1.111 99.717 1.379
201506 0.909 100.417 1.120
201509 0.427 100.417 0.526
201512 0.542 99.717 0.673
201603 0.637 100.017 0.788
201606 0.694 100.717 0.853
201609 0.317 101.017 0.388
201612 0.428 101.217 0.523
201703 0.105 101.417 0.128
201706 0.129 102.117 0.156
201709 0.124 102.717 0.149
201712 0.167 102.617 0.201
201803 0.120 102.917 0.144
201806 0.028 104.017 0.033
201809 0.057 104.718 0.067
201812 4.145 104.217 4.923
201903 2.055 104.217 2.441
201906 0.725 105.718 0.849
201909 0.371 106.018 0.433
201912 0.572 105.818 0.669
202003 0.744 105.718 0.871
202006 0.417 106.618 0.484
202009 1.444 105.818 1.689
202012 1.283 105.518 1.505
202103 1.194 107.518 1.375
202106 0.977 108.486 1.115
202109 0.851 109.435 0.962
202112 0.955 110.384 1.071
202203 0.714 113.968 0.775
202206 0.524 115.760 0.560
202209 0.987 118.818 1.028
202212 0.791 119.345 0.820
202303 0.323 122.402 0.327
202306 0.101 123.140 0.102
202309 0.140 124.195 0.140
202312 0.030 123.773 0.030

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Affimed NV  (LTS:0HL9) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Affimed NV Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Affimed NV's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Affimed NV (LTS:0HL9) Business Description

Industry
Traded in Other Exchanges
Address
Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

Affimed NV (LTS:0HL9) Headlines

No Headlines